PT - JOURNAL ARTICLE AU - Almazán, Nerea Martín AU - Rahbar, Afsar AU - Carlsson, Marcus AU - Hoffman, Tove AU - Kolstad, Linda AU - Rönnberg, Bengt AU - Pantalone, Mattia Russel AU - Fuchs, Ilona Lewensohn AU - Nauclér, Anna AU - Ohlin, Mats AU - Sacharczuk, Mariusz AU - Religa, Piotr AU - Amér, Stefan AU - Molnár, Christian AU - Lundkvist, Åke AU - Susrud, Andres AU - Sörensen, Birger AU - Söderberg-Nauclér, Cecilia TI - Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics AID - 10.1101/2021.12.23.21268321 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.23.21268321 4099 - http://medrxiv.org/content/early/2021/12/25/2021.12.23.21268321.short 4100 - http://medrxiv.org/content/early/2021/12/25/2021.12.23.21268321.full AB - Susceptibility to SARS-CoV-2 infections is highly variable, ranging from asymptomatic and mild infections in most, to deadly outcome in few. Here, we present evidence that antibodies induced by currently circulating influenza A H1N1 (flu) strains cross react with the most critical receptor binding motif of the SARS-CoV-2 spike protein that interacts with the ACE2 receptor. About 58– 68% of blood donors in Stockholm had detectable antibodies to this cross-reactive peptide, NGVEGF, and seasonal flu vaccination trended to enhance binding of inhibitory antibodies to SARS-CoV-2. This peptide also activated CD8 T cells in 20% of healthy subjects. Eleven additional CD8 T-cell peptides that cross-react with flu and SARS-CoV-2 were identified that potentially protect against SARS-CoV-2 in 40–71% of individuals, depending on their HLA type.One-Sentence Summary Flu-mediated pre-immunity to SARS-CoV-2 may protect against COVID-19 and likely affects herd immunity thresholds.Competing Interest StatementBS and AS have submitted a patent application concerning a peptide Covid19 vaccine.Funding StatementThis research was partially funded by the Swedish Research Council (VR: 2019-01736. 2017-05807. 2018-02569). The European Unions Horizon 2020 Research Innovation Program under grant 874735 (VEO). The Knut and Alice Wallenberg Foundation and the Science for Life Laboratory Uppsala (Projects: Nevermore Covid SiCoV and Molres).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee at Karolinska Institutet, Stockholm, Sweden (Dnr 2020-06333: all vaccinated subjects gave written informed consent; blood donors from blood bank were anonymous; Dnr 2020-07232: all subjects gave written informed consent; Dnr 06400: included anonymous blood samples from healthy donors (HD) in 2011 (Dnr: 01-420) and in 1996 (Dnr: 95-397 and 02-091). Ethical approval was obtained for the animal study (Dnr 16.07.2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors